Abstract
Cetuximab given concurrently with chemotherapy has shown survival benefit for patients with metastatic colon cancer. We report a case of a patient with metastatic colon cancer who developed paraneoplastic necrotizing myopathy that possibly responded to cetuximab despite lack of improvement of the underlying cancer.
MeSH terms
-
Adenocarcinoma / complications
-
Adenocarcinoma / drug therapy
-
Adenocarcinoma / secondary
-
Anti-Bacterial Agents / therapeutic use
-
Anti-Inflammatory Agents / therapeutic use
-
Antibodies, Monoclonal / administration & dosage*
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bevacizumab
-
Camptothecin / administration & dosage
-
Camptothecin / analogs & derivatives
-
Candidiasis / complications
-
Candidiasis / drug therapy
-
Cetuximab
-
Colonic Neoplasms / complications
-
Colonic Neoplasms / drug therapy
-
Colonic Neoplasms / pathology
-
Humans
-
Irinotecan
-
Klebsiella Infections / complications
-
Klebsiella Infections / drug therapy
-
Liver Neoplasms / complications
-
Liver Neoplasms / drug therapy
-
Liver Neoplasms / secondary
-
Male
-
Methylprednisolone / therapeutic use
-
Middle Aged
-
Muscular Diseases / drug therapy*
-
Muscular Diseases / etiology
-
Muscular Diseases / physiopathology
-
Paraneoplastic Syndromes / drug therapy*
-
Paraneoplastic Syndromes / etiology
-
Paraneoplastic Syndromes / physiopathology
-
Tuberculosis / complications
-
Tuberculosis / drug therapy
Substances
-
Anti-Bacterial Agents
-
Anti-Inflammatory Agents
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Bevacizumab
-
Irinotecan
-
Cetuximab
-
Methylprednisolone
-
Camptothecin